With the "Technology for the next Generation" award, we want to support young researchers and start-ups who are working to improve the future for the next generation.
Research issues often include a technological/IT component. In addition to financial support, this is where our expertise comes in. This is why we are particularly keen to support researchers and start-ups in this area.
Until 2023, the TNFG was focussed on areas directly related to the health of the next generation. From 2024, we are opening up the award to any project that aims to directly or indirectly improve the future of the next generation. This can also be explicitly from the areas of environment, sustainability, economy, etc.
Are you working on your Bachelor, Master or PhD thesis in one of the mentioned areas or do you need support? Or are you part of a startup in this field? Apply now! Or send us a Mail if you have any questions.
Application deadline: 10.6.2025
Award: 10.7.2025
The prize is valued at CHF 10'542.00. 60% of the prize is paid out and 40% provided as IT service. With IT service we think of support with data analysis, business and IT consulting, statistical studies with R, programming in Python, database cluster and computing power, webapplications, advice in choosing hard- and software, and more.
With the first-time foundation of the Technology for the Next Generation prize, we want to break new ground as part of our social commitment and have tried to choose a goal with whom a large part of our employees, customers, and society can identify. Especially as a father of three healthy children, we want to take full responsibility for our and future generations and are convinced that IT can be of great help in this area as well.
Christian Hensel, CEO
Are you interested?
Apply for yourself and your research project or start-up with an abstract, a description of the current status or prototype, schedule and references using the form and tell us how we can support you.
Contact: Dr Lukas Bäni, nextgeneration@hejuba.com
Please follow us and the tnfg in the meantime at:
Während meiner Zeit im Management einer Basel-basierten, global tätigen Consultingfirma für Pharma-, Biotech- und Medtechunternehmen, habe ich HEJUBA nicht nur für deren rasche und lösungsorientierte Unterstützung unserer internationalen Belegschaft geschätzt sondern auch für deren zukunfts- und ressourcenorientierte Ansätze und Diskussionen. Genau so habe ich HEJUBA auch bei unserer jüngsten Neugründung und bei der Unterstützung von non-profit Vereinen erlebt. Somit reflektiert der "Technology for the next Generation" – Preis in geradezu perfekter Weise die Philosophie und das Verantwortungsbewusstsein der Gründer von HEJUBA und es erfüllt mich mit Freude dieses Bestreben unterstützen zu können.
Walter Fürst, Mitgründer Luminance Health
We have been happy to receive professional support for all our needs through HEJUBA over the last two years and the fact that they actively support our target group - Scientific founders makes us doubly happy to work with them.
Douglas Haggstrom, Manager INCATE
Auch die Generation unserer Kinder soll mit Zuversicht in die Zukunft schauen können. Dafür müssen ganz viele Ideen in positive Initiativen verwandelt werden, die dann zusammen etwas Großes bewirken können. Der Forschungs-Preis von HEJUBA ist eine Einladung, diesen Weg mutig zu beschreiten. Vielen Dank und viel Erfolg!
Peter Kilian, CEO CTC Resourcing Solutions
Phaos promotes social entrepreneurship through social innovation, providing accessible services to those who wish to develop sustainable solutions for entrepreneurship and local development.
The Department of Digital Systems of the University of the Peloponnese offers programs in the fields of computer science, networks, computer hardware, and more.
The Knowledge and Uncertainty Research Lab examines the role of knowledge and its absence in the theory and application of information technology.
Alexander Heynisch is the winner of the 2024 award for his pioneering research on fighting antimicrobial resistance (AMR) through de novo protein design. AMR arises when microbes, such as bacteria, evolve and consequently fail to respond to previously effective drugs. Using Nobel Prize-winning protein design technology, Alexander develops molecules that kill bacteria through mechanisms different from traditional antibiotics. His work advances the understanding of bacterial vulnerabilities and could contribute to the development of the next generation of antibiotics to tackle this looming global health crisis.
Elena Börlin and her team at SeFit were the winners in 2023. SeFit aims to make Virtual Reality more accessible for therapists, thereby simplifying exposure therapy. Exposure therapy can be used for various purposes, such as treating anxiety disorders. The goal is now to combine VR headsets with real-life recorded scenes, an app, and a web application, along with digital biomarkers, to assist people suffering from sensory filter deficits. Sensory filter deficit is particularly known in the context of ADHD, Asperger's, and migraines, but there are other diagnoses that are also affected.
The 2022 winners are Aukera Therapeutics with "Unleashing the therapeutic potential of mTOR inhibition". Cell growth and proliferation (increase in cell number) in the human body are controlled by the protein mTOR. mTOR works in two different forms: mTOR complex 1 and mTOR complex 2. Cancer cells are generally characterized by increased cell growth and proliferation, and approximately 70 % of all cancers show increased mTOR complex 1 activity. In addition, certain neurological disorders show upregulation of mTOR complex 1 signaling. Aukera Therapeutics is developing a unique class of drugs that can selectively and safely reduce the activity of mTOR complex 1.
This year we also gave Round Table Antibiotics an honorary award in recognition of their social commitment.
This year's winner is Daniel Hauke with his research on paranoid schizophrenia. We are proud to support Daniel in this area by developing an app for early diagnosis and faster medication discovery.
Schizophrenia is a serious psychiatric illness that affects millions of people worldwide (World Health Organization). Persecution thoughts are a particularly common symptom that occurs in around 70% of all first-time patients (Freeman & Garety, 2014) and is a particularly stressful symptom for those affected. At present, however, the treatment of such symptoms is tedious and it can take several months to find the right medicament, as there are no valid predictors for the success of various drugs. The goal of our research is to develop computer-aided tests for clinicians that help predict the success of medication or potential side effects, in order to significantly shorten the time it takes to find an effective medication for a patient and to adapt the medical treatment to the individual patient. We are also testing whether these computer-assisted tests can be used beforehand to predict whether patients who are at increased risk of schizophrenia will actually get it.
The winners of the "Technology for the next Generation" prize 2019 are Asier González Seviné and Stefan Imseng from the Biozentrum, University of Basel with their project "Unleashing the clinical benefit of selective mTORC1 inhibition". To the website
Would you like to contribute to the award or project? Or do you have feedback?
Contact: Christian Hensel, c.hensel@hejuba.com
![[Translate to Englisch:]](/fileadmin/_processed_/9/4/csm_AdobeStock_467523338_3879c352f6.jpeg "[Translate to Englisch:]")
